Clinical Trials · NCT06064006
A Research Study to See How a New Medicine (NNC0487-0111) Works in People With Overweight or Obesity When Injected Under the Skin
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 125
- Start date
- Sep 2023
- Locations
- 2 sites, United States
- Primary endpoint
- PART A: Number of treatment emergent adverse events (TEAE)